顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 | 1250993-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷
• 英文名称: (1S,6R)-3-Boc-3,7-diazabicyclo[4.2.0]octane
• 英文别名: tert-butyl (1S,6R)-3,7-diazabicyclo[4.2.0]octane-3-carboxylate
• CAS: 1250993-51-1
• 化学式: C₁₁H₂₀N₂O₂
• 分子量: 212.29
• InChiKey: TUIAJQPTVCSWOB-DTWKUNHWSA-N

物化性质

• 沸点：
  295.4±40.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Fused bicyclic inhibitors of menin-MLL interaction
  申请人：Janssen Pharmaceutica NV

  公开号：US10975100B2

  公开（公告）日：2021-04-13

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

  本发明涉及可用于哺乳动物治疗和/或预防的药物制剂，尤其涉及融合双环化合物、包含此类化合物的药物组合物，以及它们作为门宁/MLL 蛋白/蛋白相互作用抑制剂的用途，可用于治疗癌症、骨髓增生异常综合征（MDS）和糖尿病等疾病。
• FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
  申请人：Janssen Pharmaceutica NV

  公开号：US20200172556A1

  公开（公告）日：2020-06-04

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.